印度儿童与青少年SARS-CoV-2重组刺突蛋白疫苗的安全性与免疫原性:2-3期随机临床试验
该2-3期观察者盲法随机试验在印度10家三级医院开展,纳入儿童(2-11岁)和青少年(12-17岁)各460名,按3:1随机接种SII-NVX-CoV2373或安慰剂。结果显示,两组抗S IgG和中和抗体几何平均滴度比相对成人均达非劣效(95%CI下限均大于0.67),疫苗组抗体滴度显著高于安慰剂组,且安全性良好,未发现特别关注的不良事件或因果相关的严重不良事件。
要点
- SII-NVX-CoV2373在儿童和青少年中相对成人的免疫应答达到非劣效标准。
- 疫苗组抗S IgG和中和抗体滴度在第36天和第180天均显著高于安慰剂组。
- 疫苗安全性良好,常见 solicited 不良事件为注射部位反应、发热、头痛、不适和疲劳。
核心结论
- SII-NVX-CoV2373在儿童和青少年中安全且耐受性良好,具有高度免疫原性,可用于儿童COVID-19疫苗接种。
研究设计与样本
- 该2-3期观察者盲法随机临床试验在印度10家三级医院开展,儿童(2-11岁)和青少年(12-17岁)各随机460名,按3:1分配至SII-NVX-CoV2373组或安慰剂组,监测179天。
主要发现
- 第36天和第180天,SII-NVX-CoV2373组抗S IgG和中和抗体滴度均显著高于安慰剂组。
- 相对成人的抗S IgG几何平均滴度比:青少年1.20(95%CI 1.08-1.34),儿童1.52(95%CI 1.38-1.67)。
- 相对成人的中和抗体几何平均滴度比:青少年1.33(95%CI 1.17-1.50),儿童1.93(95%CI 1.70-2.18)。
- 疫苗对所研究的变异株也显示免疫应答。
- 常见 solicited 不良事件包括注射部位反应、发热、头痛、不适和疲劳;无特别关注的不良事件和因果相关的严重不良事件。
关键数值与推荐
- 非劣效性判定标准为各年龄组相对成人几何平均滴度比的95%CI下限大于0.67。
- 儿童抗S IgG滴度比1.52(95%CI 1.38-1.67),青少年1.20(95%CI 1.08-1.34),均满足非劣效标准。
- 儿童中和抗体滴度比1.93(95%CI 1.70-2.18),青少年1.33(95%CI 1.17-1.50),均满足非劣效标准。
临床怎么用
- 该疫苗在儿童和青少年中安全且免疫原性高,可考虑用于儿童COVID-19疫苗接种。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The recombinant COVID-19 vaccine NVX-CoV2373 has demonstrated efficacy of approximately 90% in adults; however, its safety and efficacy in children is unknown. OBJECTIVE: To assess the noninferiority of SII-NVX-CoV2373 in children and adolescents compared to adults and to evaluate its safety in comparison with placebo. DESIGN, SETTING, AND PARTICIPANTS: This phase 2-3 observer-blind randomized clinical trial was conducted in 2 cohorts, children (aged 2 to 11 years) and adolescents (aged 12 to 17 years) between August 2021 and August 2022. Participants were randomized 3:1 to SII-NVX-CoV2373 or placebo and monitored for 179 days. The participants, study team, and laboratory staff were blinded. This was a multicenter study conducted across 10 tertiary care hospitals in India. Exclusion criteria included previous COVID-19 infection or vaccination, immunocompromised condition, and immunosuppressive medications. INTERVENTIONS: Two doses of 0.5-mL SII-NVX-CoV2373 or placebo were administered intramuscularly on days 1 and 22. MAIN OUTCOMES AND MEASURES: Primary outcomes were geometric mean titer ratio of both anti-spike (anti-S) IgG and neutralizing antibodies (NAbs) between both pediatric age groups to that of adults on day 36. Noninferiority was concluded if the lower bound of 95% CI of this ratio was greater than 0.67 for each age group. Both the antibodies were assessed for the index strain and for selected variants at various time points. Solicited adverse events (AEs) were recorded for 7 days after each vaccination, unsolicited AEs were recorded for 35 days, and serious AEs and AEs of special interest were recorded for 179 days. RESULTS: A total of 460 children in each age cohort were randomized to receive vaccine or placebo. The mean (SD) age was 6.7 (2.7) years in the child cohort and 14.3 (1.6) years in the adolescent cohort; 231 participants (50.2%) in the child cohort and 218 in the adolescent cohort (47.4%) were female. Both anti-S IgG and NAb titers were markedly higher in the SII-NVX-CoV2373 group than in the placebo group on both day 36 and day 180. The geometric mean titer ratios compared to those in adults were 1.20 (95% CI, 1.08-1.34) and 1.52 (95% CI, 1.38-1.67) for anti-S IgG in adolescents and children, respectively; while for NAbs, they were 1.33 (95% CI, 1.17-1.50) and 1.93 (95% CI, 1.70-2.18) in adolescents and children, respectively, indicating noninferiority. SII-NVX-CoV2373 also showed immune responses against variants studied. Injection site reactions, fever, headache, malaise, and fatigue were common solicited AEs. There were no AEs of special interest and no causally related serious AEs. CONCLUSIONS AND RELEVANCE: SII-NVX-CoV2373 was safe and well tolerated in children and adolescents in this study. The vaccine was highly immunogenic and may be used in pediatric vaccination against COVID-19. TRIAL REGISTRATION: Clinical Trials Registry of India Identifier: CTRI/2021/02/031554.
引用
- Gunale B, Kapse D, Kar S, et al. Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India: A Phase 2-3 Randomized Clinical Trial. JAMA Pediatr. 2023. PMID: 37523166. doi:10.1001/jamapediatrics.2023.2552
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。